Jupiter Asset Management Ltd. Lowers Position in BioCryst Pharmaceuticals, Inc. $BCRX

Jupiter Asset Management Ltd. cut its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 41.7% during the 4th quarter, Holdings Channel.com reports. The fund owned 1,197,619 shares of the biotechnology company’s stock after selling 858,296 shares during the period. Jupiter Asset Management Ltd.’s holdings in BioCryst Pharmaceuticals were worth $9,341,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the company. Deerfield Management Company L.P. grew its stake in shares of BioCryst Pharmaceuticals by 159.4% in the 3rd quarter. Deerfield Management Company L.P. now owns 12,169,000 shares of the biotechnology company’s stock worth $92,363,000 after acquiring an additional 7,477,000 shares in the last quarter. Qube Research & Technologies Ltd boosted its holdings in BioCryst Pharmaceuticals by 152.3% during the second quarter. Qube Research & Technologies Ltd now owns 2,373,489 shares of the biotechnology company’s stock worth $21,266,000 after purchasing an additional 1,432,824 shares during the last quarter. Bank of America Corp DE grew its position in BioCryst Pharmaceuticals by 97.9% in the 2nd quarter. Bank of America Corp DE now owns 2,841,155 shares of the biotechnology company’s stock worth $25,457,000 after purchasing an additional 1,405,498 shares in the last quarter. BNP Paribas Financial Markets increased its stake in BioCryst Pharmaceuticals by 1,059.7% in the 2nd quarter. BNP Paribas Financial Markets now owns 1,456,857 shares of the biotechnology company’s stock valued at $13,053,000 after buying an additional 1,331,230 shares during the last quarter. Finally, Vanguard Group Inc. increased its stake in BioCryst Pharmaceuticals by 6.1% in the 3rd quarter. Vanguard Group Inc. now owns 21,790,881 shares of the biotechnology company’s stock valued at $165,393,000 after buying an additional 1,246,633 shares during the last quarter. 85.88% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, insider Alane P. Barnes sold 150,000 shares of BioCryst Pharmaceuticals stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $9.15, for a total value of $1,372,500.00. Following the completion of the sale, the insider owned 400,703 shares of the company’s stock, valued at approximately $3,666,432.45. This trade represents a 27.24% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 5.10% of the company’s stock.

BioCryst Pharmaceuticals Trading Down 2.1%

NASDAQ:BCRX opened at $8.91 on Friday. BioCryst Pharmaceuticals, Inc. has a 12 month low of $6.00 and a 12 month high of $11.31. The firm’s 50 day moving average is $9.16 and its 200 day moving average is $8.01. The stock has a market capitalization of $2.26 billion, a PE ratio of -5.01 and a beta of 0.57.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Wednesday, May 6th. The biotechnology company reported ($2.98) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.06 by ($3.04). The firm had revenue of $156.41 million during the quarter, compared to analysts’ expectations of $151.12 million. BioCryst Pharmaceuticals had a negative return on equity of 76.36% and a negative net margin of 51.71%.The business’s quarterly revenue was up 7.5% compared to the same quarter last year. During the same period in the prior year, the business earned $0.20 earnings per share. Research analysts predict that BioCryst Pharmaceuticals, Inc. will post -2.66 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on BCRX. Weiss Ratings upgraded BioCryst Pharmaceuticals from a “sell (d-)” rating to a “hold (c)” rating in a research note on Wednesday, March 4th. Citizens Jmp lifted their price target on BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the stock a “market outperform” rating in a report on Thursday, May 7th. Royal Bank Of Canada reduced their price objective on BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating for the company in a research note on Friday, January 30th. Wedbush decreased their target price on BioCryst Pharmaceuticals from $22.00 to $21.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Finally, Wall Street Zen cut BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 9th. Nine investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $20.70.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.